Abstract:The final, formatted version of the article will be published soon. You have multiple emails registered with Frontiers: Please enter your email address: If you already have an account, please login You don't have a Frontiers account ? You can register here SARS-CoV-2 and COVID-19 impacted the world like a modern plague, stretching icy fingers across the globe. Humanity was even more horrified upon finding that this new plague came with variants, and surviving one version of the virus did not automatically grant immunity to all variants. But as has happened with previous pandemics, the deadliness and reach of COVID-19 has subsided into a slightly worrisome status quo due to the advancements of medical science and the virus' own evolution into less harmful forms. The intense scrutiny that SARS-CoV-2 and COVID-19 received during the height of their deadly assault on the world has revealed things that are now used to combat this pandemic.We now know that, unlike us, our immune system was not so surprised by SARS-CoV-2 since crossreactive immunity to SARS-CoV-2 existed prior to the COVID-19 pandemic. Cross-reactive immunity is mediated by antibodies and memory B and T cells elicited by a specific pathogen or antigen that can also react to other pathogens or antigens (1) Cross-reactivity is a main feature of adaptive immunity, which is highly favored by the recognition of small portions within protein antigens (epitopes) (2) and the poly-specificity of cognate B and T cell receptors (3,4). Human common cold coronaviruses (hCoVs) have received major attention as potential sources of crossreactive immunity to SARS-CoV-2 (5). However, immune cross-reactivity has also been reported between SARS-CoV-2 and unrelated viruses (6), bacteria (7), vaccines (8,9) and even food antigens (9). Activation of cross-reactive immunity is not always protective and can also produce immunopathology (10). Moreover, immune cross-reactivity is a two-way road and SARS-CoV-2 infection as well as COVID-19 vaccines can also induce cross-reactive immunity. Indeed, immune cross-reactivity between SARS-CoV-2 and COVID-19 vaccines with human tissues has been shown, raising the possibility that autoimmune reactivity can result from SARS-CoV-2 infection and COVID-19 vaccines (11).Clearly, pre-existing cross-reactive immunity must have a major impact in shaping the immune response to the virus and to COVID-19 vaccines, but to what extent and its contribution to protection is still undetermined. Likewise, SARS-CoV-2 and COVID-vaccines can have profound crossreactive immunological consequences that need to be investigated. In this special issue of Frontiers in Immunology about "Cross-Reactive Immunity and COVID-19," editors Aristo Vojdani, Pedro Reche, Alberto Beretta and Ahmed Yaqinuddin have gathered an impressive collection of articles investigating sources of immune cross-reactivity with SARS-CoV-2, contribution to protection, COVID-19 course and its ancillary condition, long COVID.On the face of it, it would seem that cross-reactive immunity would be a welcome weapon to wield against COVID-19. Pedro Reche, one of the editors of this collection, published an article in 2020 (8) in which he concluded, "Overall, our results clearly support that cross-reactive immunity from DTP vaccines can be protecting children against SARS-CoV-2 and could protect the general population." In 2022, Fonte et al. looked at the lower susceptibility of children to SARS-CoV-2 infection and concluded that the lower incidence and severity of the disease in children could be due to nonspecific resistance to SARS-CoV-2 generated by the childhood vaccines received by the subjects (12). ). These authors report that broadly neutralizing ability is critical for developing the next generation SARS-CoV-2 vaccine. They found that a specific homologous vaccine was insufficient for dealing with the Omicron virus variant, which had very different antigenic characteristics from the original. They also found that anti-ACE2 autoantibodies were significantly increased in all vaccinated test groups.The Omicron variant also proved problematic for Li M et al.'s study in this collection (INSERT LINK TO Article #18: Li M, Weng S, Wang Q, Yang Z, Wang X, Yin Y et al. Reduced binding activity of vaccine serum to Omicron receptor-binding domain. Front Immunol, 2022, 13: 960195, doi: 10.3389/fimmu.2022.960195). They found that vaccination contributes significantly in limiting the spread of SARS-CoV-2. However, they also found that this vaccine protection is not efficient against the Omicron variant. This was evidenced by the reduction in the binding of SARS-CoV-2 antibody-positive human sera to Omicron RBDs compared to its homogenous recombinant RBDs. We have already mentioned that the emergence of SARS-CoV-2 variants prevents acquiring general immunity to the disease. Thompson et al. investigated the impact of c -Abstract Truncated-

Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization

Pre‐existing Immunity to SARS‐CoV‐2 Associates with Strong T Cell Responses Induced by Inactivated COVID‐19 Vaccines

Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination

Effect of seasonal coronavirus immune imprinting on the immunogenicity of inactivated COVID-19 vaccination

Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response

Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity

Seasonal Coronaviruses and SARS-CoV-2: Effects of Preexisting Immunity During the COVID-19 Pandemic

SARS-CoV-2 antibody response in SARS survivors with and without the COVID-19 vaccine

Pre-existing antibodies targeting a linear epitope on SARS-CoV-2 S2 cross-reacted with commensal gut bacteria and shaped vaccine induced immunity

Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing

Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses

Clinical and laboratory features in health care volunteers with inactivated SARS-CoV-2 vaccination

Editorial: Cross-reactive immunity and COVID-19

Characterization of SARS-CoV-2-specific humoral immunity and associated factors in the healthy population post-vaccination

Neutralizing Antibodies Against SARS-CoV-2 Variants Induced by Natural Infection or Vaccination: A Systematic Review and Individual Data Meta-Analysis

Neutralizing Antibodies and Cellular Immune Response after Two Doses of Inactivated SARS-CoV-2 Vaccine in China.

Re-Evaluation and Retrospective Comparison of Serum Neutralization Induced by Three Different Types of Inactivated SARS-CoV-2 Vaccines

Heterotypic immunity from prior SARS-CoV-2 infection but not COVID-19 vaccination associates with lower endemic coronavirus incidence

Stable and Durable Antibody Responses in SARS-recovered Donors Vaccinated with Inactivated SARS-CoV-2 Vaccine

A community study of neutralizing antibodies against SARS-CoV-2 in China

Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk